| Objective: Endometrial carcinoma is one of the common gynecological malignancy, In recent years, the fatality rate caused by endometrial carcinoma exists an upward trend and becomes one of the important causes that can threaten women's health. Owing to the limitations of diagnosis method and the low specificity of endometrial cancer tumor markers, to search a new tumor markers and therapeutic targets has become a focus for researchers and clinicians. As a member of insulinlike growth factor II mRNA-binding proteins, IMP3 (insulinlike growth factor II mRNA-binding protein 3) is a novel oncofetal mRNA-binding protein,which expresses in embryonic tissues and cancers. The reasearches have showed that Imp3 genes can combine mRNA from different purpose gene to participate in mRNA transcription regulation and reverse transcript. It involves in the cell growth and differentiation process, IMP3 gene expresses excessively in malignant tumor tissues and is closely related to the occurrence and development of malignant tumor. As the most associated anti-oncogene in human malignancy, P53 plays an important role in the cell cycle regulation and inducing apoptosis. Normal wild type genes p53 as"molecular police"watched the integrity of the cell genome, whose mutation can lead to onset carcinoma. Studies have shown that mutations p53 protein have excessive expression in endometrial cancer, but no expression in normal and adenomatoid hyperplasia endometrium. In this study, we detect the expression of IMP3 and P53 in endometrial carcinoma by immunohistochemistry to elucidate their functions and relationship in the occurrence and development of endometrial carcinoma and explore the new ideas in the diagnosis and treatment of endometrial carcinoma.Methods: The samples are obtained from pathology of department of the second hospital of HeBei Medical University, concluding 35 type I endometrial carcinoma, the range of age from 42 to 78, average age 57.54±1.52; 15 type II endometrial carcinoma the range of age from 52 to 65, average age 57.07±1.08. Based on FIGO standard of 2000: stage I (17cases), stage II (13cases), stage III (15cases), stage IV (5cases); histological classification: well-differentiated (G1) (14cases), moderate-differentiated (G2) (17cases), poor-differentiated (G3) (19cases); metastasis of Lymph node 13 cases, no metastasis 27 cases. None of the patients had received radiotherapy and chemotherapy before operation and no other tumors history, diagosised correctly by routine pathological examination. There was no statistical difference of average age between the two groups. By using immunohistochemistry SP method, this study detects the expression of IMP3 and P53 gene protein in endometrial carcinoma. IMP3 gene uses placental tissue as a positive control, P53 genes uses the known breast cancer samples as the positive control group. They both take PBS to instead a resistance as negative control. The interspongioplastic substance or intranuclear stain is considerd as IMP3 positive and intranuclear brown granule is considered as P53 immunostaining. The stained results of IMP3 and P53 are measured by the Product of the percent of Positive stain and Percentage of Positive cell numbers in all congeneric cells. All the data using SPSS 13.0 software package, P<0.05 is considered significantly statistic differences.Results:1 The expression of IMP3 in the endometrial carcinoma.The location and expression of IMP3: IMP3 located mainly in: The cytoplasm of endometrial carcinoma. It expresses in two type of endometrial carcinoma. Statistics show that the positive rate of IMP3 in type I endometrial carcinoma and type II endometrial carcinoma was 31.4% and 93.3% respectively. There is a significant difference between them (P=0.000<0.05). In type II endometrial cancer,IMP3 mainly expressed in Uterine papillary serous carcinoma, which expression rate was almost to 100 %, In the clinical pathologic stage , the positive expression rate of IMP3 in III~IV group is higher than I ~II group (70% vs 36.7%, P=0.021<0.05) . There is statistically significant difference. Maybe it has a positive correlation with clinical stages. In the clinical and pathological organization classification, IMP3 protein expressed positively in G1, G2 and G3 group, respectively 21.4%,41.2 %,78.9%(P=0.003<0.05), which maybe indicate correlation with pathological classification. Compared with no lymph node metastasis, the positive expression rate of IMP3 gene was higher (41.9% vs 76.9%), the two groups was statistically significant (P=0.032<0.05).2 The expression of P53 in endometrial carcinoma.The location and expression of P53: P53 located mainly in the nucleus of endometrial carcinoma. It expressed in two type of endometrial carcinoma. Statistics show that the positive rate of P53 in type I endometrial carcinoma and type II endometrial carcinoma is 42.6% and 73.3% respectively. There is a significant difference between them (P=0.048<0.05). In the clinical pathologic stage, the positive expression rate of P53 in III~IV group is higher than I ~ II group (66.7% vs 40%, P=0.038<0.05) .There is statistically significant differences. In the clinical and pathological organization classification, P53 expressed positively in G1, G2 and G3 group, respectively 28.6%, 33.3%, 83.3 %(P=0.002<0.05). P53 protein expression concerned with pathological classification. P53 gene increases as the tumor cell differentiation degree level decreases. Compared with no lymph node metastasis, the positive expression rate of P53 gene was higher (55.6% vs 61.5%), the two groups was statistically significant (P=0.032<0.05). P53 gene expressed positive rate in lymph node metastasis and no lymph node metastasis respectively, 61.5% and 55.6%, there was no significant difference (P =0.072>0.05), Still can't think about the lymph node metastasis.3 Statistical results show that there is correlation between the expression IMP3 and P53 gene in endometrial carcinoma.Conclusions:1 Compared with type I endometrial carcinoma, IMP3 protein as a high specificity of cytoplasm markers mainly expresses in type II endometrial carcinoma. It can be used to distinguish between two types of endometrial carcinoma.IMP3 gene in type II endometrial cancer mainly expressed in Uterine papillary serous carcinoma, which reveals that IMP3 gene may be involved in the onset of type II endometrial carcinoma.2 IMP3 gene closely correlated with clinical stages, histological classification, lymph node metastasis, which reveals that IMP3 gene may be involved in cell growth and differentiation process. It can be used to judge the prognosis of malignant.3 P53 mutation tends to occur in type II endometrial carcinoma, which indicated that P53 maybe participate in the onset of the type II endometrial carcinoma.4 P53 gene increases as the decreases of tumor cell differentiation degree level and the increases of Clinical pathologic stage, but no correction with the lymph node metastasis.5 There is correlation between the expression IMP3 and P53 gene in endometrial carcinoma, which could supply some clues that IMP3 and P53 gene are likely to have synergy effect to some extent during carcinogenesis and development of endometrial carcinoma.
|
PDF Full Text Request